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Introduction
Many postsynaptic genes and processes have been linked to neuro-
developmental disorders (1), and it is increasingly apparent that pre-
synaptic dysfunction is another major contributory pathway. Rare 
variants have been identified in genes that regulate presynaptic pro-
cesses that ultimately affect neurotransmitter release (2). However, 
the final effector mechanisms that couple neuronal activity to syn-
aptic vesicle (SV) fusion at central synapses have not yet been impli-
cated in the pathophysiology of any neurodevelopmental disorder.
The synaptotagmins are a family of integral SV proteins 
required for the coupling of activity-dependent calcium influx to 
SV fusion at central synapses (3). Synaptotagmin-1 (SYT1) is the cal-
cium sensor for fast synchronous evoked neurotransmitter release, 
since its deletion results in the specific ablation of this event (4, 
5). SYT1 triggers SV fusion first by binding calcium via highly con-
served cytoplasmic C2A and C2B domains, followed by penetra-
tion of the plasma membrane bilayer by a series of hydrophobic 
residues within these domains (6–8). This event may either desta-
bilize the plasma membrane, lowering the energy barrier for SV 
fusion, or act as an electrostatic switch, bringing the SV and target 
membranes in close apposition to drive their fusion (9). Ablation of 
SYT1 expression also affects SV endocytosis, resulting in a slowing 
of retrieval kinetics (10–13). The calcium-binding ability of SYT1 
may also be required to accelerate SV retrieval, since experimental 
mutagenesis of specific residues that coordinate calcium binding 
did not rescue SV retrieval kinetics when expressed in SYT1-knock-
out neurons (14). Thus SYT1 exerts a complex influence on synaptic 
transmission, with both fundamental and facilitatory roles in neu-
rotransmitter release and SV endocytosis, respectively.
Despite the key role for SYT1 in presynaptic function, there 
has been no confirmation to date that this gene and the molecu-
lar events it controls are essential for human neurodevelopment, 
because no individual with a pathogenic SYT1 variant (Synapto-
tagmin-1, OMIM *185605) has been identified. However, likely 
pathogenic variants have been reported in SYT14 and SYT2, asso-
ciated with spinocerebellar ataxia and peripheral neuropathy, 
respectively, suggesting that impaired synaptotagmin function 
can be pathogenic, although via mechanisms that are likely to dif-
fer between isoforms (15, 16). We report a case of a human neuro-
developmental disorder associated with a rare variant in SYT1 and 
demonstrate that this variant exerts a dominant negative effect on 
SV cycling at mammalian central nerve terminals.
Synaptotagmin-1 (SYT1) is a calcium-binding synaptic vesicle protein that is required for both exocytosis and endocytosis. 
Here, we describe a human condition associated with a rare variant in SYT1. The individual harboring this variant presented 
with an early onset dyskinetic movement disorder, severe motor delay, and profound cognitive impairment. Structural MRI 
was normal, but EEG showed extensive neurophysiological disturbances that included the unusual features of low-frequency 
oscillatory bursts and enhanced paired-pulse depression of visual evoked potentials. Trio analysis of whole-exome sequence 
identified a de novo SYT1 missense variant (I368T). Expression of rat SYT1 containing the equivalent human variant in WT 
mouse primary hippocampal cultures revealed that the mutant form of SYT1 correctly localizes to nerve terminals and is 
expressed at levels that are approximately equal to levels of endogenous WT protein. The presence of the mutant SYT1 
slowed synaptic vesicle fusion kinetics, a finding that agrees with the previously demonstrated role for I368 in calcium-
dependent membrane penetration. Expression of the I368T variant also altered the kinetics of synaptic vesicle endocytosis. 
Together, the clinical features, electrophysiological phenotype, and in vitro neuronal phenotype associated with this dominant 
negative SYT1 mutation highlight presynaptic mechanisms that mediate human motor control and cognitive development.
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roll, pull to stand, and cruise around a playpen. At 10 years (current 
age), he can stand unsupported and has taken some independent 
steps. He sometimes reaches for objects, but has an immature grip. 
His visual behavior is severely immature, fixing momentarily on 
bright objects and not consistently following objects or faces. He 
turns toward voices and sounds but does not turn to his own name. 
He shows no evidence of verbal comprehension, uses no speech or 
communicative gesture, does not follow single component instruc-
tions, and shows no evidence of recognition memory. Eye contact 
is absent, and he does not imitate actions or vocalizations. When 
agitated, he chews and bites his hands. He appears to be aware of 
pain. There has been no developmental regression.
Vineland Adaptive Behaviour Scales II, survey interview form 
(17) was completed with a parent. At chronological age 8 years 3 
months, developmental age–equivalent attainments were as follows: 
gross motor skills, 8 months; fine motor skills, 6 months; communi-
cation, daily living skills, and socialization, all less than 1 month.
Weight and height remain on the 50th percentile. Head circum-
ference at 2 years 9 months was 49.5 cm (9th to 25th percentile) and 
at 8 years 11 months was 53 cm (25th percentile) (UK cross-sectional 
reference data, 1996; ref. 18). He is not dysmorphic and has no neu-
rocutaneous or musculoskeletal abnormalities. Cardiac, respiratory, 
and abdominal examinations are normal. Neurological examination 
reveals no tremor or fasciculation, no facial asymmetry, and normal 
eye movements. Drooling is present but not severe. Axial tone is 
reduced. Peripheral tone is normal throughout all 4 limbs, with no 
Results
Clinical history. The proband is the second child of nonconsan-
guineous parents of European descent. There is no family history 
of neurological or neurodevelopmental disability. There were no 
medical complications of pregnancy, and he was born by sponta-
neous vaginal delivery at 34 weeks gestation (birth weight 50th 
percentile; no resuscitation required). Congenital features were 
bilateral talipes equinovarus (corrective surgery at 9 months) and 
bilateral esotropia (corrective surgery at 13 months).
During infancy, he was hypotonic and hypokinetic. By 3 years, 
he developed dystonic posturing of the limbs and choreoathetoid 
movements. By 8 years (Supplemental Video 1; supplemental 
material, including video legend, available online with this article; 
doi:10.1172/JCI79765DS1), neurological symptoms had progressed 
to a severe paroxysmal mixed hyperkinetic movement disorder, 
affecting his face, upper limbs, and lower limbs bilaterally. Chorea 
dominates, especially of the lower limbs. Ballismus of the lower 
limbs is also present. There is intermittent dystonic posturing of all 
affected body areas. Abnormal movements are maximal at night 
and worsen before and after purposeful motor activity. No seizures 
have been observed. Bulbar functions are intact, with no swallowing 
difficulties. There is no evidence for autonomic instability. Symp-
toms have been insensitive to trialled medications (sodium valpro-
ate, carbamazepine, chloral betaine, sedating antihistamines).
All domains of development are severely to profoundly delayed. 
He sat independently at 4 years of age, and at 8 years of age he could 
Figure 1. MRI and EEG in proband with de novo heterozygous SYT1 I368T mutation. (A) MRI at 2 years; (B) EEG at 2 years (awake); (C) EEG at 2 years (asleep); 
(D) MRI at 8 years; (E) EEG at 8 years (awake); (F) EEG at 8 years (asleep). T1-weighted MR images (midline sagittal slices) are presented in radiological orienta-
tion. See also Supplemental Figure 1 (spectral analysis).
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age-matched controls and 41–68 μV2 for infant controls), elevated 
relative power within the theta range as compared with controls, 
and reduced relative power in all other frequency bands, with a 
shift in theta band distribution toward posterior electrodes.
In summary, clinical EEG recordings point toward extensive 
disturbance to cerebral electrical activity with developmental evo-
lution of abnormal features, no localized cortical focus, and no 
features diagnostic of a recognized electroclinical syndrome.
Evoked potentials highlight unusual abnormalities of cortical pro-
cessing. Visual evoked potentials (VEPs) were recorded to assess 
basic properties of cortical excitability in a noninvasive manner 
not requiring subject cooperation (Figure 2). The proband’s VEPs 
to single-pulse flash stimulation (awake, alert) were consistently 
reproducible and within normal limits for morphology of the N70 
and P100 components, but with reduced amplitude and increased 
latency in comparison with a healthy age-matched control. 
Paired-pulse stimulation revealed enhanced depression of the 
VEP response to the second-flash stimulus, sensitive to interpulse 
interval (IPI). At IPI of 500 ms, the proband’s N70/P100 ampli-
tude to second flash was 80% to 85% of the amplitude to first 
flash. At IPI of 200 ms, the amplitude of the P100 was reduced 
to 45% to 50% of the amplitude to first flash, and at IPI of 100 
ms, second VEP amplitude was further reduced to 33% to 40%. 
In a healthy age-matched control child, P100 amplitude elicited 
by second flash showed no decrement at any IPI, consistent with 
adult data indicating that paired-pulse depression is not normally 
apparent until an IPI of less than 150 ms (19) and developmental 
data indicating that VEP responses during rapid stimulation are 
normally mature by age 3 years (20).
Auditory event-related potentials (AEPs) were recorded to 
assess the maturation of cortical information processing (Sup-
plemental Figure 2). Comparison with a developmental data set 
obtained using the same recording equipment and stimulation 
protocol indicated that the morphology and latency of the pro-
band’s AEPs at age 8 years were similar to those of healthy infants 
aged 9 to 14 months (21). In contrast, age-appropriate AEPs were 
observed in children with epilepsy and intellectual disability due 
to known structural pathology, indicating that infant-like cortical 
information processing observed in the proband is not typical of 
severe neurodevelopmental disorder.
Identification of SYT1 I368T variant. Whole-exome sequencing 
was performed on DNA from the proband and both parents within 
the UK10K project (Rare Diseases Sample Sets, www.uk10k.org). 
ankle clonus. Power in all 4 limbs is normal and symmetrical. Deep 
tendon reflexes are easily elicited in the upper limbs and brisk in the 
lower limbs. Plantar responses are flexor. Optic fundoscopy is normal.
In summary, the main features of this childhood-onset disor-
der are involuntary movements, including dystonia and chorea, 
accompanied by severely delayed motor development and pro-
found intellectual disability, with no evidence of overt seizures, 
autonomic dysfunction, bulbar dysfunction, or developmental 
regression. There was no apparent in utero, perinatal, or postnatal 
injury or infection to suggest an acquired cause. Clinical investi-
gations including extensive metabolic testing and chromosome 
analysis at 500 kb resolution were normal (Supplemental Meth-
ods). This severe and unexplained phenotype is not typical of any 
known congenital syndrome.
MRI revealed no developmental or degenerative structural brain 
abnormality. MRI of the brain was obtained using standard clinical 
acquisition sequences at 1.5T at ages 2 years 2 months and 8 years 
11 months. No neuroradiological abnormalities were detected, 
and maturation was within normal limits for chronological age at 
both time points (Figure 1). Magnetic resonance spectroscopy at 
age 8 years was within normal limits.
EEG demonstrates marked electrophysiological disturbance. 
Clinical EEG recordings were carried out in view of unexplained, 
progressive neurological symptoms at ages 2 years and 8 years 
(Figure 1). At both ages, background activity was diffusely slow and 
of high amplitude. At 2 years, the record was dominated by long 
periods (10 seconds to 1 minute) of very high-amplitude (up to 600 
μV) notched slow waves (2–3 Hz). During drowsiness, abnormal 
discharges were almost continuous, and midcentral 5–6 Hz spike 
activity appeared. Sleep was characterized by intermittent showers 
of high-amplitude, notched slow-wave activity (0.5–4 Hz) originat-
ing posteriorly with variable spread. At 8 years, abnormal activity 
had evolved into bursts of low-frequency (5–6 Hz), high-amplitude 
oscillations, present during wakefulness and persistent into sleep, 
maximal over anterior regions. These low-frequency oscillatory 
bursts were not linked to external stimulation and not simultane-
ous with motoric abnormalities or altered behavior. Occasional 
2- to 3-second runs of high-amplitude spike-wave complexes were 
observed over frontocentral regions during sleep only.
Global electrophysiological properties were quantified via 
spectral analysis at age 8 years and compared with age-matched 
and infant controls (Supplemental Figure 1). The proband showed 
increased global power (205.6 μV2 compared with 34 to 40 μV2 for 
Figure 2. VEPs in proband with de novo heterozygous SYT1 I368T muta-
tion and age-matched control. Paired-pulse flash stimulation at IPI of 
200 ms, sweep length 500 ms. (A) Healthy 8-year-old child: amplitude of 
VEP2 is at least 80% of the amplitude of VEP1. (B) Proband: amplitude of 
VEP2 waveform is around 50% of the amplitude of VEP1. Note difference 
in VEP1 amplitude and latency between the proband and control. See also 
Supplemental Figure 2 (auditory evoked potentials).
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which is highly conserved across evolution, with isoleucine at 
position 368 absolutely conserved from Drosophila melanogaster 
to vertebrates (Figure 3).
The SYT1 I368T variant affects both SV exocytosis and endo-
cytosis. To determine whether the de novo SYT1 variant identi-
fied in the proband alters presynaptic function, we examined the 
effect of expressing rat SYT1 containing the equivalent mutation 
(corresponding to I367T in rat) in primary cultures of WT mouse 
hippocampal neurons. WT SYT1 and mutant SYT1 (I368T) were 
tagged at their N-terminal luminal domain with pHluorin, a 
green fluorescent protein with enhanced pH sensitivity (23), 
to enable visualization of their intracellular localization and 
quantification of SV recycling. When expressed in neurons, the 
localization of mutant SYT1I368T-pHluorin was identical to that 
of SYT1WT-pHluorin, indicating normal targeting to nerve ter-
minals (Figure 4, A and B). This is reflected by a similar coeffi-
cient of variation value for both SYT1WT-pHluorin and SYT1I368T-
pHluorin, which reports how punctate their distribution is along 
the neuronal axon (24): (SYT1WT-pHluorin 116.2 ± 7.3; SYT1I368T-
pHluorin 124.0 ± 7.5, n = 3 for both; P = 0.50). Both SYT1WT-
pHluorin and SYT1I368T-pHluorin were expressed to equivalent 
levels, with total SYT1 expression levels increased by approxi-
mately 1.6- to 1.8-fold over background endogenous SYT1 (fold 
expression over endogenous: SYT1WT-pHluorin 1.60 ± 0.14, 
n = 3; SYT1I368T-pHluorin 1.77 ± 0.18, n = 4; P = 0.53). Thus, the 
SYT1I368T mutant is expressed in mouse neurons at an approxi-
mately equal proportion to that of endogenous SYT1 (mimicking 
the heterozygous nature of the variant in the proband).
We next determined whether expression of the SYT1 I368T 
mutant affected normal SV recycling, since a mutation of the equiv-
alent isoleucine to glutamate in Drosophila resulted in a reduction in 
evoked neurotransmitter release (25). This was achieved by moni-
toring the traffic of SYT1-pHluorin. SYT1-pHluorin has little or no 
fluorescence when inside SVs, which have a pH of approximately 5.5 
(26). Therefore exocytosis can be viewed as an increase in fluores-
cence and retrieval of SYT1-pHluorin from the plasma membrane 
This included 76 probands with moderate-to-severe intellectual 
disability and unaffected parents. No coding variants in published 
genes associated with intellectual disability or congenital move-
ment disorders were detected in the proband. Subtraction analysis 
to identify rare de novo variants in the proband compared with the 
parental DNA identified 9 variants using DeNovoGear (Supple-
mental Table 1). Of these variants, 6 were identified as being non-
coding sequence variants (intronic, 3′ UTR sequence, or within a 
noncoding gene). Of the remaining 3 variants, 2 were identified 
as common polymorphisms rs649216 and rs145771593, leav-
ing a single heterozygous de novo variant for further analysis at 
(chr12:79842738, hg19) within SYT1. The heterozygous de novo 
nonsynonymous variant that results in an isoleucine-to-threonine 
substitution at position 368 (I368T) was confirmed by Sanger 
sequencing (Figure 3).
The variant is absent from the 1000 Genomes data (22), more 
than 13,000 alleles from the Exome Variant Server (http://evs.
gs.washington.edu/EVS/), and more than 122,000 alleles from 
the ExAC cohort (http://exac.broadinstitute.org/). This vari-
ant was unique in the UK10K cohort of n = 9464 alleles in 4,732 
patients with a range of clinical diagnoses (UK10K Neurodevelop-
ment and Obesity sample sets). More specifically, the neurode-
velopment sample set included 2,598 individuals with autism or 
schizophrenia. An additional cohort of 1,425 cases with intellec-
tual disability, of which 160 cases had an associated movement 
disorder, were screened for this variant, and no further cases were 
identified. In addition, there are no reported cases in DECIPHER 
where SYT1 alone has been deleted or duplicated (https://deci-
pher.sanger.ac.uk/). These data indicate that the I368T variant 
observed in the patient is an extremely rare mutational event.
Analysis of coding variant frequencies within human SYT1 
in publicly available databases (ExAC, EVS) shows a remark-
able lack of variation in this protein, as there is only a single 
coding polymorphism recorded at V420I within 2 amino acids 
of the 3′ end of the 422 amino acid protein. The I368T variant 
lies within the C2B calcium-binding region of the SYT1 protein, 
Figure 3. Identification, confirmation, 
and evolutionary analysis of de novo 
SYT1 variant. (A) Sanger sequence 
analysis confirming the de novo SYT1 
variant. Sequence chromatograms dem-
onstrate the presence of the variant in 
the proband and the reference allele in 
both parents. (B) Alignment of cross-
species SYT1 protein sequences, show-
ing the position of the mutation I368T 
at the absolutely conserved isoleucine 
residue within a highly conserved region 
of amino acid sequence.
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fluorescence decrease was monitored. SYT1WT-pHluorin fluores-
cence decayed with first-order kinetics as observed previously (13, 
14, 23). Intriguingly, SYT1I368T-pHluorin fluorescence returned to 
baseline levels with faster kinetics than SYT1WT-pHluorin (Figure 
4E), suggesting the SYT1 mutation affects its retrieval from the 
plasma membrane during SV endocytosis. However, this accelera-
tion in SYT1I368T-pHluorin retrieval does not affect the amount of 
this reporter resident on the plasma membrane (Figure 4F).
To determine whether expression of the I368T mutant specifi-
cally affected SYT1 trafficking or had a general dominant negative 
effect on SV recycling, we examined the effect of coexpressing SYT1 
fused to the cyan protein mCerulean (mCer) (28) with a separate 
pHluorin reporter, vGLUT-pHluorin (29). The vGLUT-pHluorin 
fluorescence response was observed during challenge with 1,200 
action potentials in the presence of bafilomycin A1 as before. We 
found no significant difference in the size of the SV recycling pool 
between neurons expressing mCer-SYT1WT and mCer-SYT1I368T 
(Figure 5A, SYT1WT-pHluorin 55.3% ± 2.3%, n = 11; SYT1I368T-pHlu-
orin 51.3% ± 1.2% of total SV pool, n = 9; P = 0.16). When the rate of 
vGLUT-pHluorin fluorescence increase was calculated, a signifi-
cant slowing was observed in mCer-SYT1I368T–expressing neurons 
compared with those expressing mCer-SYT1WT (Figure 5B). Thus, 
as a decrease (since SV endocytosis is the rate-limiting step rather 
than SV acidification; ref. 23). To specifically report SV exocytosis, 
cultures were incubated with bafilomycin A1 to block the activity of 
the vesicular proton pump, thereby preventing quenching of pHluo-
rin fluorescence by SV acidification after endocytosis (27).
When cultures expressing either SYT1WT-pHluorin or SYT1I368T-
pHluorin were challenged with a train of 1,200 action potentials in 
the presence of bafilomycin A1, both reporters displayed a similar 
peak response when normalized to the total SV pool (Figure 4C). 
Thus, the presence of mutant SYT1 did not affect the number of 
SVs that were mobilized by action potential stimulation (SYT1WT-
pHluorin 62.3% ± 1.9%, n = 8; SYT1I368T-pHluorin 55.2% ± 3.6% 
of total SV pool, n = 6; P = 0.09). However, the rate of SV exocy-
tosis was greatly reduced in neurons expressing SYT1I368T-pHlu-
orin compared with SYT1WT-pHluorin (Figure 4D). In summary, 
mutant SYT1 retards the speed of evoked SV fusion events when 
expressed in WT neurons.
SYT1 has a key facilitatory role in SV endocytosis; therefore, 
we also determined whether SYT1I368T-pHluorin displayed altered 
retrieval during endocytosis. Cultures expressing either SYT1WT-
pHluorin or SYT1I368T-pHluorin were challenged with a train of 
300 action potentials delivered at 10 Hz, and the poststimulation 
Figure 4. Effect of I368T mutation on SYT1 localization 
and activity-dependent trafficking. (A and B) Hippocampal 
neurons were transfected with either SYT1WT-pHluorin or 
SYT1I368T-pHluorin. Representative images show a similar 
punctate distribution of SYT1WT-pHluorin (WT, A) and SYT1I368T-
pHluorin (I368T, B) along axonal segments after exposure to 
alkaline imaging buffer. Image is displayed in false color, with 
warmer colors indicating more fluorescence intensity. Arrows 
represent the localization of both pHluorin reporters at nerve 
terminals. Scale bar: 1 μm. (C and D) Transfected neurons were 
stimulated with a train of 1,200 action potentials at 10 Hz in 
the presence of 1 μM bafilomycin to prevent vesicle reacidi-
fication and subsequently exposed to NH4Cl to reveal total 
pHluorin fluorescence (n = 8 WT, n = 6 I368T). (C) Time course 
of mean ΔF/F0 of SYT1-pHluorin ± SEM, normalized to NH4Cl. 
*P < 0.05, over time indicated (2-way ANOVA). (D) Exocytosis 
time constant (τ) determined by fitting a single-phase asso-
ciation curve to the data presented in C. Data are presented as 
mean ± SEM (n = 8 WT and n = 6 I368T). *P < 0.03 (t test). (E) 
Neurons were stimulated with a train of 300 action potentials 
at 10 Hz. Graph displays the time course of mean ΔF/F0 of 
SYT1-pHluorin ± SEM, normalized to the peak of stimulation 
(n = 7 WT, n = 6 I368T). *P < 0.05, over time indicated (2-way 
ANOVA). (F) Surface SYT1-pHluorin fluorescence, determined 
by normalizing SYT1-pHluorin fluorescence to 100% in alkaline 
buffer and 0% in acidic buffer. Data are presented as mean ± 
SEM. n = 4. P = 0.86 (t test).
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the SYT1I368T mutant has a dominant negative effect on the rate of 
SV fusion events in mammalian central nerve terminals.
To determine whether the expression of mCer-SYT1I368T influ-
ences SV endocytosis, cultures transfected with vGLUT-pHluorin 
and either mCer-SYT1I368T or mCer-SYT1WT were stimulated with 
a train of 300 action potentials (10 Hz) in the absence of bafilo-
mycin. Neurons expressing mCer-SYT1I368T displayed a faster 
recovery in the vGLUT-pHluorin response when compared with 
mCer-SYT1WT (Figure 5C), suggesting this mutant also displays 
dominant effects on global SV endocytosis kinetics.
Discussion
The identification and characterization of an extremely rare de 
novo variant in SYT1 associated with a severe and unusual neu-
rodevelopmental phenotype indicate that dysregulation of rapid, 
synchronous SV fusion and subsequent recycling can have a pro-
found impact on human neurological function and cognitive devel-
opment. Investigation of this case exemplifies the opportunity to 
illuminate mechanisms of neurodevelopmental disorder when 
large-scale genome-sequence analysis is combined with experi-
mental neuroscience and suggests that investigations of presyn-
aptic mechanisms will yield further clinically relevant discoveries.
To test the hypothesis that the identified de novo nonsynony-
mous variant in SYT1 might explain the proband’s phenotype, 
we first examined the properties of the gene and variant accord-
ing to existing literature. Postnatal SYT1 expression is abundant 
throughout the cerebral cortex, whereas SYT2 is the predomi-
nant isoform in the brain stem, cranial nerves, and spinal cord 
(30–32), consistent with the severe cognitive impairment but 
normal respiratory function and neurological examination in the 
proband. Human transcriptome data indicate relatively low SYT1 
expression in the striatum (33); however, rat in situ hybridization 
data point to restricted expression by dopaminergic cells in the 
substantia nigra pars compacta, in keeping with basal ganglia dys-
function and involuntary movement disorder (31). Human neo-
cortical and hippocampal SYT1 expression increase during post-
natal life in parallel with synaptogenesis (33, 34), in keeping with 
the evolving postnatal symptoms and severely restricted cognitive 
development in the proband.
To trigger SV fusion, SYT1 must bind calcium and then pen-
etrate the lipid bilayer (6–8). The mutated isoleucine residue is 
highly conserved across all species and is flanked by aspartate 
residues that coordinate calcium binding. Furthermore, it is one 
of a number of hydrophobic residues within both the C2A and C2B 
domains that are essential for calcium-dependent membrane pen-
etration (35). Global substitution of these hydrophobic residues 
with neutral amino acids inhibits calcium-dependent phospholip-
id binding (7, 8) and prevents rescue of neurotransmitter release in 
SYT1 KO mouse neurons (13). Conversely, substitution with more 
hydrophobic residues enhances both phospholipid binding and 
neurotransmitter release (7, 8, 13, 35). The variant residue in this 
study has been directly implicated in calcium-dependent mem-
brane penetration by the C2B domain: heterozygous mutagenesis 
of this residue to the polar amino acid glutamate in Drosophila 
permitted morphologically normal brain development and SV bio-
genesis, but an abolition of evoked synchronous neurotransmitter 
release, resulting in lethal hypokinesia (25). We therefore hypoth-
esized that the patient’s heterozygous variant would have a delete-
rious impact on evoked, synchronous neurotransmitter release, 
influencing global properties of cerebral activity and affecting 
motor and cognitive development.
To test this prediction directly, we carried out in vitro func-
tional studies to examine the impact of the identified heterozygous 
SYT1 variant on evoked SV cycling in WT mammalian neurons. 
This resulted in overexpression of SYT1 above endogenous levels; 
however, the ratio of mutant to WT SYT1 (0.8:1) approximated to 
that expected of heterozygous expression. Expression of the equiv-
alent mutation in rat SYT1 (I367T) resulted in a dominant nega-
tive effect on SV fusion kinetics reported by either SYT1-pHluorin 
or vGLUT-pHluorin; since the same SV phenotype was observed 
with both reporters, we suggest that heterozygous expression of 
SYT1I368T slows exocytosis either by limiting evoked synchronous 
release or via desynchronization, leading to increased asynchro-
nous release. The dominant negative effect could result from 
Figure 5. Effect of I368T mutation on activity-dependent SV cycling. Neurons were cotransfected with vGLUT-pHluorin and either mCer-SYT1WT (WT) or 
mCer-SYT1I368T (I368T). (A and B) Neurons were stimulated with a train of 1,200 action potentials at 10 Hz in the presence of bafilomycin as described for 
Figure 4C. (A) Average time course of ΔF/F0 for vGLUT-pHluorin ± SEM, normalized to NH4Cl (n = 11 WT, n = 9 I368T. *P < 0.05, over time indicated (2-way 
ANOVA). (B) Average exocytosis time constant (τ) determined by fitting single-phase association curve to data presented in A. Data are presented as mean 
± SEM (n = 11 WT, n = 9 I368T). *P < 0.02 (t test). (C) Neurons were stimulated with a train of 300 action potentials at 10 Hz. Graph displays the average time 
course of ΔF/F0 of vGLUT-pHluorin ± SEM, normalized to peak of stimulation (n = 8 WT, n = 9 I368T). *P < 0.05, over time indicated (2-way ANOVA).
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the need for multiple soluble NSF attachment protein receptor 
(SNARE) complexes to fuse a SV; thus, the displacement of endog-
enous SYT1 by SYT1I368T in some complexes results in inefficient 
fusion events (23). Alternatively, the deficiency in SV fusion could 
stem from multimerization of mutant SYT1I368T with WT SYT1. 
The C2AB domains of SYT1 can oligomerize at membranes into 
ring-like structures in vitro that dissociate upon addition of Ca2+ 
(36). Formation of this structure is proposed to prevent comple-
tion of the SNARE complex assembly, with calcium removing this 
potential fusion clamp. Thus mutant SYT1I368T may act in a domi-
nant negative manner by oligomerizing with WT SYT1 and reduc-
ing the efficiency of calcium-triggered disassembly.
SYT1 is also required for efficient SV endocytosis in central 
nerve terminals, with homozygous knockout of SYT1 resulting 
in retarded SV retrieval kinetics (10–14). We observed that the 
retrieval of SYT1I368T was faster than that of SYT1WT and that SV 
endocytosis occurred more quickly with SYT1I368T expression com-
pared with SYT1WT. Accelerated SV endocytosis has been observed 
before, in neurons derived from stonin 2–knockout mice (37). In 
the absence of stonin 2, an endocytic adaptor protein selective 
for SYT1, accelerated endocytosis was accompanied by increased 
expression of SYT1 at the plasma membrane due to defective SYT1 
retrieval (37). However, we saw no surface stranding of SYT1I368T, 
suggesting the observed acceleration of SV endocytosis is due to 
an alternative, currently unresolved mechanism.
The effects of the SYT1 I368T variant on evoked SV fusion 
and endocytosis may influence the fidelity of neurotransmission. 
Because of this, we evaluated the electrophysiological features 
of the proband to identify any abnormalities that could plausibly 
reflect presynaptic dysfunction. We observed reduction in the 
amplitude and prolonged time course of single-flash VEP, in keep-
ing with reduced cortical excitability, but not specifically indicative 
of presynaptic dysfunction. A more unusual feature was enhanced 
frequency-dependent paired-pulse depression of the VEP. Short-
term synaptic depression is dependent on the probability of SV 
fusion, including replenishment of SV pools and recovery of cal-
cium-sensitive release mechanisms, including SYT1 (38, 39), with 
presynaptic recovery predominating over postsynaptic desensiti-
zation at central mammalian synapses (40). Xu et al. (41) exten-
sively characterized a SYT1 mouse model and identified dynamic 
regulatory functions for SYT1 during burst activity, showing that 
its knockdown impaired cortical learning via abnormal filtering of 
high-frequency activity. The proband’s background EEG showed 
extensive low-frequency oscillations suggestive of impaired filter-
ing of thalamocortical activity. Collectively, electrophysiological 
observations in the proband lead us to propose that abnormal SV 
cycling associated with this dominant negative variant disturbs 
the dynamic properties of synaptic transmission, severely limiting 
postnatal functional brain organization, as indexed by infant-like 
auditory evoked responses.
In summary, abnormal kinetics of neurophysiological function 
have been uncovered by in vivo assessment of a child with a het-
erozygous SYT1 mutation and in vitro investigation of the muta-
tion in isolated mouse neurons. There is accumulating evidence 
that defects in the presynaptic vesicle release and reuptake cycle 
can contribute to the pathophysiology of severe neurodevelop-
mental disorders. Deletion of the SV proteins synapsin I or synap-
sin II in mice results in epilepsy, learning impairments, and social-
behavioral deficits that mimic symptoms of autism (42). Cultures 
derived from synapsin I– or II–knockout mice have functional SV 
pools of reduced size, and this effect is not rescued by expression 
of synapsin variants identified in individuals with autism and sei-
zure disorders (43, 44). Mutations in syntaxin-binding protein 1 
(STXBP1; Munc-18) have been associated with epileptic encepha-
lopathy, intellectual disability, and movement disorders (45–47), 
and recently mutations in syntaxin-1B (STX1B) have also been 
associated with temperature-sensitive seizure disorders (48), indi-
cating that SNARE complex assembly, SV docking, and priming 
are important steps in the pathway leading to SV fusion (49). Mice 
lacking the SV protein synaptophysin (SYP) display behavioral 
deficits consistent with the association between human SYP muta-
tions and intellectual disability (50, 51). Cultured neurons derived 
from SYP-deficient mice display reduced endocytic rate and SV 
cargo-retrieval defects (24, 52). Furthermore, expression of SYP 
mutations identified in individuals with X-linked intellectual dis-
ability failed to rescue this cargo-retrieval defect, suggesting that 
disturbed kinetics of endocytosis contribute to the pathophysiol-
ogy of this rare inherited neurodevelopmental disorder (53). We 
propose that SYT1 mutation and consequent disturbance to the 
SV fusion step of exocytosis and endocytosis be considered within 
this emerging group of presynaptic disorders, in which dynamic 
disruption to neurotransmission influences functional neurode-
velopment, leading to a range of movement disorders and intel-
lectual impairments.
Methods
Patient recruitment and phenotyping. Clinical phenotyping was carried 
out by clinical geneticists and pediatric neurologists. Neuroimaging 
and neurophysiology investigations at 2 time points were qualitatively 
reviewed by a pediatric neuroradiologist and pediatric neurophysiolo-
gist. Clinical investigations, EEG acquisition, and analysis protocols 
are provided in Supplemental Methods.
Exome sequencing and bioinformatics. Exome sequencing and 
trio de novo analysis were carried out for the proband and both 
parents as described in Supplemental Methods. Raw data are avail-
able at the European Genome-phenome Archive (study acces-
sion number EGAS00001000128; data set accession EGAD-
00001000416). The de novo SYT1 variant was confirmed by 
Sanger sequencing.
Functional studies. Materials for pHluorin constructs, plasmid 
preparation, and hippocampal neuronal culture methods are detailed 
in Supplemental Methods. Immunolabeling and fluorescent imag-
ing were performed as described previously (24), and protocols are 
detailed in Supplemental Methods. In all cases, n refers to the number 
of independent experiments performed.
Statistics. Statistical analyses were performed using GraphPad 
Prism software, and all data were tested by Student’s t test (2-tailed) 
except time-course experiments, which were assessed by 2-way 
ANOVA. P < 0.05 was considered significant.
Study approval. Institutional review board approval was obtained 
from the Multi-Centre Research Ethics Committee for Scotland 
(study reference 03/0/014). The proband’s parents provided written, 
informed consent for all aspects of the study, including publication of 
identifiable material.
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